Physician profile
Eric Vaillant
NPI 1992963227
$14,472.00
in general payments reported to CMS, 2019-2025
10 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,432 · 2020: $6,515 · 2021: $1,682 · 2022: $1,163 · 2023: $361 · 2024: $162 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $5,000.00 | 2020 | |
| Fortis Surgical, LLC | $3,537.42 | 2019 | |
| Zimmer Biomet Holdings, INC. | $2,050.04 | 2020-2025 | Rosa, Comprehensive Shoulder System, Persona |
| Smith+Nephew, INC. | $1,544.31 | 2020-2023 | Evos, Invisiknot |
| Cdc Medical LLC | $1,244.09 | 2021-2022 | |
| Arthrex, INC. | $916.35 | 2019-2022 | |
| Vericel Corporation | $115.38 | 2019 | |
| Arteriocyte Medical Systems, INC. | $28.72 | 2024-2025 | Magellan |
| Bioventus LLC | $20.17 | 2023 | Durolane |
| Stryker Corporation | $15.52 | 2023 | Easyfuse, Ortholoc 2 Lapifuse, Augment Injectable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vaillant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.